Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: The trinity randomized, double-blind, 12-week, parallel-group study

American Journal of Cardiovascular Drugs

Volumn 12, Issue 4, 2012, Pages 233-243

  Chrysant, Steven G ^a   Littlejohn, Thomas ^b   Izzo, Joseph L ^c   Kereiakes, Dean J ^d   Oparil, Suzanne ^e   Melino, Michael ^f   Lee, James ^f   Fernandez, Victor ^f   Heyrman, Reinilde ^f  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NC   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d The Carl & Edyth Lindner Center for Research & Education   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f DAIICHI SANKYO INC   (United States)

Author keywords

angiotensin receptor antagonists; antihypertensives; calcium channel antagonists; hypertension; thiazide diuretics.

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN;

ARTHRALGIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; JOINT SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEGRO; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84863975902     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11634160-000000000-00000     Document Type: Article

References (43)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303 (20): 2043-50
2. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988- 1994 and 1999-2004. Hypertension 2008; 52 (5): 818-27
3. Ferdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol 2007; 6 (2): 67-71
4. Ferdinand KC. Management of high blood pressure in African Americans and the 2010 ISHIB consensus statement: meeting an unmet need. J Clin Hypertens (Greenwich) 2010; 12 (4): 237-9
5. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56 (5): 780-800
6. Kola LD, Sumaili EK, Krzesinski JM. How to treat hypertension in blacks: review of the evidence. Acta Clin Belg 2009; 64 (6): 466-76
7. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125 (1): 188-97
8. Yoon SS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008 [NCHS data brief, no. 48]. National Center for Health Statistics [online]. Available from URL: http:// www.cdc.gov/nchs/data/databriefs/db48.pdf [Accessed 2011 Apr 25]
9. Ferdinand KC. Coronary artery disease in minority racial and ethnic groups in the United States. Am J Cardiol 2006; 97 (2A): 12A-9A
10. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics: 2010 update. A report from the American Heart Association. Circulation 2010; 121 (7): 948-54
11. Douglas JG, Ferdinand KC, Bakris GL, et al. Barriers to blood pressure control in African Americans: overcoming obstacles is challenging, but target goals can be attained. Postgrad Med 2002; 112 (4): 51-62
12. Jamerson KA, Basile J. Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich) 2008; 10 (1 Suppl. 1): 40-8
13. Levine RS, Foster JE, Fullilove RE, et al. Black-white inequalities in mortality and life expectancy, 1933-1999: implications for healthy people 2010. Public Health Rep 2001; 116 (5): 474-83
14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805-16
15. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32 (7): 1252-69
16. Jolly S, Vittinghoff E, Chattopadhyay A, et al. Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med 2010; 123 (9): 811-8
17. Mohtashemi M, Levins R. Qualitative analysis of the all-cause black-white mortality crossover. Bull Math Biol 2002; 64 (1): 147-73
18. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
19. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115 (21): 2761-88
20. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163 (5): 525-41
21. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
22. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4 (6): 393-404
23. Moulton SA. Hypertension in African Americans and its related chronic diseases. J Cult Divers 2009; 16 (4): 165-70
24. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48 (5): 418-25
25. Gerber BS, Cho YI, Arozullah AM, et al. Racial differences in medication adherence: A cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother 2010; 8 (2): 136-45
26. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713-9
27. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399-407
28. Ferdinand KC, Ferdinand DP. Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther 2008; 6 (10): 1357-66
29. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121-58
30. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
31. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31
32. Ferdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans: why we need to do better. J Clin Hypertens (Greenwich) 2006; 8 (1 Suppl. 1): 21-30
33. Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288 (19): 2421-31
34. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich ) 2003; 5 (3): 202-9
35. Chalmers J, Joshi R, Kengne AP, et al. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens 2008; 26 (3 Suppl.): S21-7
36. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients.AmJ Hypertens 2002; 15 (12): 1042-9
37. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich) 2010; 12 (1): 3-13
38. Tobe S, Kawecka-Jaszcz K, Zannad F, et al. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich ) 2007; 9 (2):120-7
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
40. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21 (5): 875-86
41. Weir MR, Zappe D, Orloski LA, et al.How early should blood pressure control be achieved for optimal cardiovascular outcomes? J Hum Hypertens 2011; 25 (4): 211-7
42. Staessen JA, Thijs L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22 (4): 847-57
43. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363 (9426): 2049-51